Document:

<PAGE>

                                                                    EXHIBIT 10.6

                      ------------------------------------

                            ASSET PURCHASE AGREEMENT

                         -------------------------------

                                  BY AND AMONG

                              SYMCO, INCORPORATED,
                                SYMBIOTICS, INC.

                                       AND

                            QUINCY INVESTMENTS CORP.

                                  JULY 22, 2005

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                     Page
                                                                                     ----
<S>                                                                                  <C>
ARTICLE I SALE AND TRANSFER OF ASSETS...........................................        1

    1.01     Purchased Assets...................................................        1

    1.02     Excluded Assets....................................................        2

    1.03     Assumption of Liabilities..........................................        3

    1.04     Purchase Price and Payment for Assets..............................        3

    1.05     Earn Out Amount....................................................        3

    1.06     Payment of Earn Out Amount.........................................        4

    1.07     Disputes of Earn Out Calculation...................................        4

    1.08     Purchase Price Allocation..........................................        5

ARTICLE II CLOSING..............................................................        5

    2.01     Closing............................................................        5

    2.02     Deliveries by the Company..........................................        5

    2.03     Buyer's Deliveries at Closing......................................        6

ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY.......................        7

    3.01     Corporate Existence and Qualification..............................        7

    3.02     Authority, Approval and Enforceability.............................        7

    3.03     Conflicts..........................................................        7

    3.04     No Proceedings.....................................................        8

    3.05     Financial Statements...............................................        8

    3.06     Compliance with Laws...............................................        8

    3.07     Litigation.........................................................        8

    3.08     Assets of the Business.............................................        8

    3.09     Commitments........................................................        8
</TABLE>

                                      -i-
<PAGE>

<TABLE>
<S>                                                                                    <C>
    3.10     Insurance..........................................................        9

    3.11     Inventories........................................................       10

    3.12     Suppliers and Customers............................................       10

    3.13     Products...........................................................       10

    3.14     Transactions With Affiliates.......................................       10

    3.15     Operations Since May 31, 2005......................................       10

    3.16     Taxes..............................................................       11

    3.17     Intentionally Omitted..............................................       12

    3.18     Intellectual Property..............................................       12

    3.19     Environmental; Health; Safety......................................       12

    3.20     No Undisclosed Liabilities.........................................       12

    3.21     Accounts Receivable................................................       13

    3.22     Investment Representations.........................................       13

    3.23     Other Information..................................................       14

ARTICLE IV REPRESENTATIONS AND WARRANTIES OF BUYER..............................       14

    4.01     Corporate Existence and Qualification..............................       14

    4.02     Authority, Approval and Enforceability.............................       15

    4.03     No Proceedings.....................................................       15

    4.04     No Conflict........................................................       15

    4.05     Financing..........................................................       15

ARTICLE V CONDITIONS TO THE COMPANY'S AND BUYER'S OBLIGATIONS...................       16

    5.01     Conditions to Obligations of the Company...........................       16

    5.02     Conditions to Obligations of Buyer.................................       16

    5.03     Disclosure Supplement..............................................       17

    5.04     Name Change........................................................       17
</TABLE>

                                      -ii-
<PAGE>

<TABLE>
<S>                                                                                    <C>
ARTICLE VI ADDITIONAL AGREEMENTS................................................       17

    6.01     Further Assurances.................................................       17

    6.02     Publicity..........................................................       17

    6.03     Conduct of the Business Prior to the Closing Date..................       18

    6.04     Confidential Information...........................................       18

    6.05     Transition.........................................................       18

    6.06     Intentionally Omitted..............................................       18

    6.07     Exclusivity........................................................       18

    6.08     Covenant Not to Compete............................................       19

ARTICLE VII INDEMNITY...........................................................       19

    7.01     Indemnification....................................................       19

    7.02     Notice of Asserted Liability.......................................       20

    7.03     Opportunity to Defend..............................................       20

    7.04     Limitations........................................................       21

    7.05     Right of Set-Off...................................................       21

ARTICLE VIII MISCELLANEOUS......................................................       21

    8.01     Brokers............................................................       21

    8.02     Costs and Expenses.................................................       22

    8.03     Notices............................................................       22

    8.04     Governing Law, Jurisdiction, Venue, Waiver and Jury Trial..........       23

    8.05     Entire Agreement; Amendments and Waivers...........................       23

    8.06     Binding Effect and Assignment......................................       23

    8.07     Remedies...........................................................       24

    8.08     Exhibits and Schedules.............................................       24

    8.09     Multiple Counterparts..............................................       24
</TABLE>

                                      -iii-
<PAGE>

<TABLE>
<S>                                                                                    <C>
    8.10     References and Construction........................................       24

    8.11     Survival...........................................................       24

    8.12     Attorneys' Fees....................................................       24

    8.13     Termination........................................................       25

    8.14     Bulk Sales Laws....................................................       25

ARTICLE IX DEFINITIONS..........................................................       25

    9.01     Action.............................................................       25

    9.02     Affiliate..........................................................       25

    9.03     Assets.............................................................       25

    9.04     Business Day.......................................................       26

    9.05     Closing Date.......................................................       26

    9.06     Code...............................................................       26

    9.07     Collateral Agreements..............................................       26

    9.08     Contract...........................................................       26

    9.09     Court Order........................................................       26

    9.10     Encumbrances.......................................................       26

    9.11     Financial Statements...............................................       26

    9.12     GAAP...............................................................       26

    9.13     Governmental Authorities...........................................       26

    9.14     Intellectual Property..............................................       26

    9.15     Inventory..........................................................       27

    9.16     Knowledge..........................................................       27

    9.17     Legal Requirements.................................................       27

    9.18     Liabilities........................................................       27

    9.19     Naturade...........................................................       27
</TABLE>

                                      -iv-
<PAGE>

<TABLE>
<S>                                                                                                              <C>
    9.20     Permits........................................................................................       27

    9.21     Person.........................................................................................       28

    9.22     Taxes..........................................................................................       28

    9.23     Tax Returns....................................................................................       28
</TABLE>

                                LIST OF SCHEDULES
<TABLE>
<S>                                                                             <C>
Schedule 1.01(a)............................................................                       Business Contracts
Schedule 1.01(b)............................................................                    Intellectual Property
Schedule 1.01(d)............................................................                          Telephone Lines
Schedule 1.01(e)............................................................                                Inventory
Schedule 1.01(f)............................................................                       Business Documents
Schedule 1.01(g)............................................................                             Other Rights
Schedule 1.01(h)............................................................                      Accounts Receivable
Schedule 1.02...............................................................                          Excluded Assets
Schedule 1.03(a)............................................................                      Assumed Liabilities
Schedule 1.04(c)............................................................                      Net Working Capital
Schedule 1.08...............................................................                Purchase Price Allocation
Schedule 3.01...............................................................    Qualifications as Foreign Corporation
Schedule 3.05...............................................................                     Financial Statements
Schedule 3.07...............................................................                               Litigation
Schedule 3.09(a)............................................................                                Contracts
Schedule 3.10...............................................................                                Insurance
Schedule 3.12...............................................................                  Suppliers and Customers
Schedule 3.13...............................................................                                 Products
Schedule 3.14...............................................................                   Affiliate Transactions
Schedule 3.18...............................................................                    Intellectual Property
Schedule 3.20...............................................................                             Indebtedness
Schedule 3.21...............................................................                      Accounts Receivable
</TABLE>

                                LIST OF EXHIBITS

Exhibit A     -   Form of Note
Exhibit B-1   -   Consulting Agreement with Douglas Wyatt
Exhibit B-2   -   Consulting Agreement with David Brown
Exhibit C         Transition Services Agreement
Exhibit D     -   Trademark License Agreement
Exhibit E         Form of Guaranty
Exhibit F         Form of Assignment and Assumption Agreement (Assumed
                  Liabilities)

                                      -V-
<PAGE>

                            ASSET PURCHASE AGREEMENT

            THIS ASSET PURCHASE AGREEMENT (this "Agreement") is made and entered
into as of July __, 2005 ("Agreement Date"), by and among Quincy Investments
Corp., a Bahamas International Business Company (the "Buyer"), Symco,
Incorporated, a Nevada corporation ("Symco") and Symbiotics, Inc., an Arizona
corporation ("Symbiotics" and together with Symco, the "Company").

                                    RECITALS

            A. The Company is engaged in the business of selling its line of
health-related products to retailers (the "Business").

            B. Buyer desires to purchase, and Company desires to sell, the
operating assets of the Company, upon the terms and subject to the conditions
set forth herein.

                                    AGREEMENT

            NOW, THEREFORE, in consideration of the premises and of the mutual
                                 ARTICLE I

                                   ARTICLE I
                           SALE AND TRANSFER OF ASSETS

            1.01 Purchased Assets. On the terms and subject to the conditions of
this Agreement, on the Closing Date (as defined in Section 2.01 hereof), the
Company shall sell, convey, transfer and deliver to the Buyer, and the Buyer
shall purchase, acquire and accept as of the Closing Date, all of the right,
title and interest of the Company in and to the Business and all of the assets,
properties and rights of the Company of every kind and description wherever
located, tangible and intangible, related to the Business, except for the
Excluded Assets (collectively, the "Assets"), other than the Excluded Assets,
free and clear of all Encumbrances. The Assets shall include, but not be limited
to:

                  (a) All rights under any purchase orders and Contracts
      (collectively, the "Business Contracts") relating to the Business and
      related exclusively or primarily to the Assets, including, but not limited
      to, those that are identified in Schedule 1.01(a), including, without
      limitation, the right to all of the revenue therefrom related to any
      Products sold before the Closing Date;

                  (b) All goodwill and other general intangibles associated with
      the Business and related exclusively or primarily to the Assets, and all
      copyrights, patents, trade names, trademarks, service marks, logos, domain
      names, whether registered or unregistered, applications for the foregoing,
      including, but not limited to, those as more fully identified in Schedule
      1.01(b), and other trade secrets, processes, formulae, inventions,
      research and development work, technical information, production data,
      blueprints and specifications, licenses, permits, governmental approvals,
      authorizations and operation contracts, license agreements, know-how and
      similar property, customer lists, lists of suppliers, cost sheets, bills
      of material and any other intellectual property

                                      -1-
<PAGE>

      and intangible assets that are owned by the Company or to which the
      Company possesses rights that are used in the Business including all
      Intellectual Property;

                  (c) All books, files, operating data and records of the
      Company relating to the Business (the "Books and Records"), excluding
      accounting and tax books and records, including, but not limited to,
      federal, state and local tax filings and records, general ledgers, general
      journals, books of original entry, and further excluding corporate
      administrative books and records, including minute books and stock
      certificate books;

                  (d) All telephone lines, telephone numbers and telephone
      listings used by the Company in the Business, including, but not limited
      to, those more fully identified on Schedule 1.01(d) (the "Telephone
      Lines");

                  (e) The Company's Inventory as more fully identified on
      Schedule 1.01(e) hereto, which Schedule shall be updated as of the Closing
      Date to reflect changes in the ordinary course of business;

                  (f) The benefit of all confidentiality, non-competition,
      non-solicitation, non-disclosure and similar protective agreements or
      instruments, all manufacturers' warranties on tangible personal property,
      and all other agreements relating to the Business which inure to the
      Company's benefit, including, but not limited to, those more fully
      identified on Schedule 1.01(f) (the "Business Documents");

                  (g) All known and unknown, liquidated or unliquidated,
      contingent or fixed rights, choses in action or causes of action of every
      nature and kind which the Company has or may have against any third party
      relating to the Assets, including, but not limited to, those more fully
      identified in Schedule 1.01(g) (the "Other Rights");

                  (h) All accounts receivable of the Company, including, but not
      limited to, those more fully identified on Schedule 1.01(h) hereto, which
      Schedule shall be updated as of the Closing Date to reflect changes from
      the Agreement Date through the Closing Date (the "Accounts Receivable");

                  (i) All Actions, credits, rights of setoff of any kind, and
      all rights under and pursuant to all indemnities, warranties,
      representations and guarantees made by suppliers, manufacturers,
      contractors or other third parties arising before, on or after the Closing
      Date and relating exclusively or primarily to the Assets or any Assumed
      Liabilities, and the right to collect damages or proceeds in connection
      therewith;

                  (j) All goods and services and all other economic benefits to
      be received subsequent to the Closing Date which arise out of prepayments
      and payments by Seller prior to the Closing Date and relating exclusively
      or primarily to the Business.

            1.02 Excluded Assets. Those assets of Company specifically
identified on Schedule 1.02, including cash and the Purchase Price, are excluded
from the term "Assets" and therefore from the sale contemplated hereby.

                                      -2-
<PAGE>

            1.03 Assumption of Liabilities.

                  (a) Buyer will assume (a) the current accounts payable of the
      Company set forth on Schedule 1.03(a) and existing on the Closing Date and
      (b) the obligations of the Company under the contracts set forth on
      Schedule 1.03(a) (the "Assumed Liabilities").

                  (b) Except with respect to the Assumed Liabilities, Buyer
      shall in no event assume or be responsible for any Liabilities of the
      Company or relating to the Business, contingent or otherwise, known or
      unknown. The Assets shall be sold and conveyed to Buyer free and clear of
      all Encumbrances. Without limiting the generality of the foregoing, in no
      event shall Buyer assume or be responsible for: (i) any income, property,
      franchise, sales, use or other tax of the Company or any filing
      requirements or obligations with respect thereto arising out of or
      resulting from the sale of the Assets hereunder (all such taxes to be paid
      by the Company) or any transaction of the Company prior to or subsequent
      to the execution of this Agreement; and (ii) any liabilities, obligations,
      or costs resulting from any claim or lawsuit or other proceeding relating
      to the Assets or naming the Company or any successor thereof as a party
      and arising out of events, transactions, or circumstances occurring or
      existing prior to the Closing Date.

            1.04 Purchase Price and Payment for Assets. As payment in full for
the Assets:

                  (a) Buyer will, at Closing, pay all outstanding amounts owed
      under those credit facilities set forth on Schedule 3.20 and shall deliver
      to the Company a promissory note in the form attached hereto as Exhibit A
      (the "Note"), payable to the Company in the principal amount of
      $2,000,000, (i) minus the amount necessary to repay such credit facilities
      set forth on Schedule 3.20, and (ii) subject to adjustment pursuant to
      Section 1.04(c).

                  (b) In addition, the Buyer will pay the Company the sum of
      $60,000 in cash on the date that is fifteen (15) days after the Closing
      Date and an additional $60,000 in cash every thirty (30) days thereafter
      until the Note is paid in full, in accordance with Exhibit A (the "Cash
      Payment") (the principal amount of the Note (as adjusted pursuant to
      Section 1.04(c)), the Cash Payment and the Earnout Amount (as defined in
      Section 1.05) are collectively referred to herein as the "Purchase
      Price").

                  (c) The principal amount of the Note may be adjusted at
      Closing based upon changes in the Company's Inventory, accounts payable
      and accounts receivable in accordance with Schedule 1.04(c).

                  (d) In addition to the Purchase Price, Buyer shall pay to the
      Company the Earn Out Amount set forth in Section 1.05.

            1.05 Earn Out Amount. For a three (3) year period following the
Closing Date, (the "Earn Out Period"), Buyer shall pay to the Company (in
accordance with Exhibit A) ten percent (10%) of the amount of the increase in
contribution profit of the Business over the Baseline Amount based on the sale
of the Company's products (the "Earn Out Amount") commencing on the first day of
the month following the Closing Date and ending on the last day

                                      -3-
<PAGE>

of the twelfth (12th) month thereafter and continuing on each consecutive twelve
(12) month period thereafter for a period of three (3) years (the "Yearly Earn
Out Period"). The contribution profit shall be determined by calculating the
gross sales of the Company's products less cost of goods sold, direct product
promotional expenses, discounts, allowances, product returns, coupons, rebates,
commissions and freight (the "Earn Out Calculation"). The "Baseline Amount" is
$2,000,000. In determining the contribution profit of the Company, there shall
be no allocation of Buyer's general and administrative expenses.

            1.06 Payment of Earn Out Amount. Not later than 60 days after the
end of each Yearly Earn Out Period, Buyer shall pay the Earn Out Amount to the
Company and provide to the Company (i) a report setting forth the Earn Out
Calculation, including such schedules and data as may be appropriate to support
such calculation. The Company and its accountants shall be entitled to review
the Earn Out Calculation and any working papers, trial balances and similar
materials relating to the Earn Out Calculation prepared by Buyer or its
accountants. Buyer shall also provide the Company and its accountants with
timely access, during Buyer's normal business hours, to Buyer's personnel,
properties, books and records to the extent related to the determination of the
Earn Out Calculation.

            1.07 Disputes of Earn Out Calculation.

                  (a) Within 30 days after the Company's receipt of the Earn Out
      Calculation pursuant to Section 1.06, the Company may notify Buyer in
      writing that it disagrees with the Earn Out Calculation. Within 30 days
      after notification by the Company that it disagrees with the Earn Out
      Calculation, the Company must provide Buyer with such reports and
      calculations that set forth the basis for any disputed amounts in the Earn
      Out Calculation (the "Company's Report"). Except as otherwise provided in
      this Section 1.07(a), all costs and expenses associated with the Company's
      Report shall be borne by the Company. If Buyer concurs with the
      adjustments proposed by the Company, or if Buyer does not object thereto
      in a writing delivered to the Company within 30 days after Buyer's receipt
      of the Company's Report, the calculations set forth in such Company's
      Report shall become final and shall not be subject to further review,
      challenge or adjustment, absent fraud, and Buyer will immediately pay to
      the Company the difference between the Earn Out Amount and the amount
      determined in the Company's Report. Further, if such adjustments are equal
      to or greater than Five Thousand Dollars ($5,000.00), Buyer shall
      reimburse the Company for its reasonable, out-of-pocket costs in preparing
      the Company's Report. If the Company does not submit a Company's Report
      within the 30-day period provided herein, then the Earn Out Calculation as
      calculated by Buyer shall become final and shall not be subject to further
      review, challenge or adjustment, absent fraud.

                  (b) In the event that the Company and Buyer do not resolve the
      disagreements set forth in the Company's Report within 30 days after the
      date of the Company's Report, then such disagreements shall be referred to
      a recognized firm of independent certified public accountants selected by
      mutual agreement of the Company and Buyer (the "Settlement Accountants"),
      and the determination of the Settlement Accountants shall be final and
      shall not be subject to further review, challenge or adjustment, absent
      fraud, and Buyer or the Company, where appropriate, will

                                      -4-
<PAGE>

      immediately pay the difference between the Earn Out Amount and the amount
      determined by the Settlement Accountants. The Settlement Accountants shall
      use their best efforts to reach a determination not more than 45 days
      after such referral.

                  (c) The costs and expenses of the Settlement Accountants shall
      be paid by the Company if the Earn Out Calculation, as determined by the
      Settlement Accountants, is greater than the Earn Out Calculation set forth
      in the Buyer's Earn Out Calculation, and the difference is less than Five
      Thousand Dollars ($5,000.00), or if Buyer's Earn Out Calculation was
      greater than the Earn Out Calculation finally determined by the Settlement
      Accountants. If the Earn Out Calculation, as determined by the Settlement
      Accountants, is greater than the Earn Out Calculation set forth in the
      Buyer's Earn Out Calculation and the difference is equal to or greater
      than Five Thousand Dollars ($5,000.00), such costs and expenses of the
      Settlement Accountants shall be paid by Buyer.

            1.08 Purchase Price Allocation. The Purchase Price shall be
allocated among the Assets as set forth on Schedule 1.08 within ten (10) days of
the Closing Date. The parties acknowledge that such allocation fairly reflects
the fair market value of the Assets, and will use such allocation in reporting
for all federal, state and local tax purposes.

                                   ARTICLE II
                                     CLOSING

            2.01 Closing. The closing of the transactions contemplated hereby
(the "Closing") shall be held within 14 days of the execution of this Agreement
at the offices of Naturade, Inc., 14370 Myford Rd., Suite 100, Irvine, CA 92606.
The date upon which the Closing occurs is hereinafter referred to as the
"Closing Date." The Closing shall be deemed effective as of the close of
business of the Business on the Closing Date.

            2.02 Deliveries by the Company. At or prior to the Closing, the
Company shall deliver to Buyer:

                  (a) certified copies of the resolutions of the Board of
      Directors and the stockholders of the Company authorizing the transactions
      set forth herein;

                  (b) all licenses, bills of sale, assignments and other
      documents, if any, conveying to Buyer and vesting in Buyer good, clear and
      marketable title of record to all of the Assets;

                  (c) possession of all originals and copies of agreements,
      instruments, documents, books, records, files and other data and
      information within the possession of the Company that constitute part of
      the Assets (collectively, the "Records"); provided, however, that the
      Company may retain (1) copies of any Records that the Company is
      reasonably likely to need for complying with requirements of law; and (2)
      copies of any Records that in the reasonable opinion of the Company will
      be required in connection with the performance of its obligations under
      Legal Requirements;

                                      -5-
<PAGE>

                  (d) executed copy of a Consulting Agreement between the Buyer
      and Douglas Wyatt in the form attached as Exhibit B-1 (the "Wyatt
      Consulting Agreement");

                  (e) executed copy of a Consulting Agreement between the Buyer
      and David Brown in the form attached as Exhibit B-2 (the "Brown Consulting
      Agreement", and together with the Wyatt Consulting Agreement, the
      "Consulting Agreements");

                  (f) executed copy of a Transition Services Agreement between
      the Buyer and the Company in the form attached as Exhibit C (the
      "Transition Services Agreement");

                  (g) executed copy of a Trademark License Agreement between the
      Buyer and the Company in the form attached as Exhibit D (the "License
      Agreement");

                  (h) a certificate of good standing of the Company issued as of
      a recent date by the Secretary of State of the State of Nevada and
      Arizona; and

                  (i) such other documents and instruments as may be necessary
      to effect the transactions contemplated by this Agreement.

            2.03 Buyer's Deliveries at Closing. On the Closing Date, the Buyer
shall deliver to the Company the following:

                  (a) an executed Note in the form attached as Exhibit A;

                  (b) executed Guaranty of the obligations under the Note by
      Peter H. Pocklington, in the form attached as Exhibit E;

                  (c) an executed counterpart of the Consulting Agreement;

                  (d) an executed counterpart of the Transition Services
      Agreement;

                  (e) an executed counterpart of the License Agreement;

                  (f) evidence of the repayment of the credit facilities set
      forth on Schedule 3.20;

                  (g) evidence of the assumption of the Assumed Liabilities
      pursuant to an Assignment and Assumption Agreement in the form attached as
      Exhibit F;

                  (h) an executed Assignment and Assumption Agreement, pursuant
      to which the Buyer will assign all of its rights and obligations under
      this Agreement and the Collateral Agreements to Naturade; and

                  (i) such other documents and instruments as may be necessary
      to effect the transactions contemplated by this Agreement.

                                      -6-
<PAGE>

                                  ARTICLE III
                  REPRESENTATIONS AND WARRANTIES OF THE COMPANY

            The Company hereby represents and warrants to Buyer that:

            3.01 Corporate Existence and Qualification. Symco is a corporation
duly organized, validly existing and in good standing under the laws of the
State of Nevada. Symbiotics is a corporation duly organized, validly existing
and in good standing under the laws of the State of Arizona. The Company has the
corporate power to own, manage, lease and hold its properties and to carry on
its Business as and where such properties are presently located and such
business is presently conducted. The Company is duly qualified as a foreign
corporation to do business, and is in good standing in each jurisdiction where
the character of the Company's Assets or the nature of the Company's business
requires such qualification, except where the failure to so qualify or to be in
good standing would not have a material adverse effect on Company's business,
operations, properties, prospects, the Assets or condition (financial or
otherwise) (a "Material Adverse Effect"). The Company is qualified as a foreign
corporation and is in good standing in each jurisdiction set forth in Schedule
3.01 attached hereto.

            3.02 Authority, Approval and Enforceability. This Agreement has been
duly executed and delivered by the Company and the Company has all requisite
power and legal capacity to execute and deliver this Agreement and all
Collateral Agreements executed and delivered or to be executed and delivered in
connection with the transactions provided for hereby, to consummate the
transactions contemplated hereby and by the Collateral Agreements, and to
perform its obligations hereunder and under the Collateral Agreements. This
Agreement and each Collateral Agreement to which the Company is a party
constitutes, or upon execution and delivery will constitute, the legal, valid
and binding obligation of such party, enforceable in accordance with its terms,
except as such enforcement may be limited by general equitable principles or by
applicable bankruptcy, insolvency, moratorium, or similar laws and judicial
decisions from time to time in effect which affect creditors' rights generally.

            3.03 Conflicts. The execution and delivery by the Company of this
Agreement and each Collateral Agreement, and the performance by it of its
obligations hereunder and thereunder, does not and will not:

                  (a) Violate any provision of the certificate of incorporation
      or bylaws of the Company;

                  (b) Violate any provision of any Legal Requirement relating to
      the Business, the Assets or the Assumed Liabilities, or require a
      registration, filing, application, notice, consent, approval, order,
      qualification, authorization, designation, declaration or waiver with, to
      or from any Governmental Authority;

                  (c) Require a consent, approval or waiver from, or notice to,
      any party to a Contract, or result in a breach of, constitute (with or
      without due notice or lapse of time or both) a default under, result in
      the acceleration of material obligations, loss of material benefit or
      increase in any material Liabilities or fees under, or create in any party
      the right to terminate, cancel or modify, any Contract; or

                                      -7-
<PAGE>

                  (d) Result in the creation of any Encumbrance upon any
      material Asset.

            3.04 No Proceedings. No suit, action or other proceeding is pending
or, to the Knowledge of the Company, threatened before any Governmental
Authority seeking to restrain the Company or prohibit its entry into this
Agreement or prohibit the Closing, or seeking damages against the Company or its
properties as a result of the consummation of this Agreement.

            3.05 Financial Statements. Schedule 3.05 sets forth (a) unaudited
statements of certain assets and certain Liabilities of the Business as of
December 31, 2004, together with related statements of revenues, costs and
expenses of the Business for the twelve-month period ending December 31, 2004
(the "Annual Financial Statements"), (b) unaudited statements of certain assets
and Liabilities of the Business as of May 31, 2005 (the "Interim Balance
Sheet"), and (c) unaudited income statements of the Business for the five-month
period ending on May 31, 2005 (collectively, with the Annual Financial
Statements and the Interim Balance Sheets, the "Financial Statements"). The
Financial Statements (i) are in accordance with the books and records of the
Company in all material respects; (ii) present fairly, in all material respects,
the financial position of the Business for the respective periods there ended;
and (iii) have been prepared in accordance with the Company's normal practices
for the Business (which practices are in accordance with GAAP, except for (A)
the absence of footnotes and other disclosures required by GAAP and (B) with
respect to the Interim Balance Sheet and the unaudited income statements of the
Business for the five-month period ending on May 31, 2005, normal year end
adjustments, consistently applied with prior periods).

            3.06 Compliance with Laws. The Company is and has been in compliance
in all material respects with any and all Legal Requirements applicable to the
Company.

            3.07 Litigation. Except as otherwise set forth on Schedule 3.07,
there is no Action against the Company pending or, to the Knowledge of the
Company, threatened in any court or before or by any Governmental Authority, or
before any arbitrator, and to the Knowledge of the Company, there is no basis
for any such Action and there is no Court Order to which the Business is
subject.

            3.08 Assets of the Business. The Company has and will have as of the
Closing Date good and marketable title to the Assets, free and clear of any and
all Encumbrances, except for those Encumbrances which will be released on or
before the Closing Date. Except with respect to the Excluded Assets, the Assets
comprise all of the properties, assets (including, without limitation, computer
software and licenses therefor) and rights of the Company which relate to the
conduct of the Business as presently conducted and are adequate to conduct the
Business as presently conducted by the Company.

            3.09 Commitments.

                  (a) With respect to the Assets, except as otherwise set forth
      on Schedule 3.09(a), the Company is not a party to or bound by any of the
      following, whether written or oral:

                                      -8-
<PAGE>

                        (i) any Contract that cannot by its terms be terminated
            by the Company with 90 days' or less notice without penalty or whose
            term continues beyond one year after the date of this Agreement;

                        (ii) any contract or commitment for capital expenditures
            by the Company in excess of $10,000 per calendar quarter in the
            aggregate;

                        (iii) any lease or license, whether as landlord, tenant,
            licensor or licensee;

                        (iv) any agreement, contract, indenture or other
            instrument relating to the borrowing of money or the guarantee of
            any obligation or the deferred payment of the purchase price of any
            asset;

                        (v) any partnership, joint venture or other similar
            agreement;

                        (vi) any contract with any Affiliate of the Company
            relating to the provision of goods or services by or to the Company;

                        (vii) any agreement that purports to limit the Company's
            freedom to compete freely in any line of business or in any
            geographic area;

                        (viii) any asset purchase agreements, stock purchase
            agreements, and other acquisition or divestiture agreements and
            similar Contracts, including any Contracts relating to the sale,
            lease or disposal of any Assets relating to the Business (other than
            sales of Inventory in the ordinary course of business); and

                        (ix) any other Contract that is material to the business
            of the Company.

                  (b) All of the Contracts listed or required to be listed in
      Schedule 3.09(a) and all of the Business Contracts are valid, binding and
      in full force and effect; the Company has not been notified or advised by
      any party thereto of such party's intention or desire to terminate or
      modify any such Contract in any respect and neither the Company nor, to
      the Knowledge of the Company, any other party thereto is in breach of any
      of the terms or covenants of any such Contract. Following the Closing,
      Buyer will be entitled to all of the benefits of the Company under each
      Business Contract that constitutes part of the Assets.

                  (c) The Company is not a party to or bound by any Contract or
      Contracts, the terms of which were arrived at by or otherwise reflect less
      than arm's-length negotiations or bargaining.

            3.10 Insurance. Schedule 3.10 sets forth a complete and correct list
of all insurance policies presently in effect that relate to the Company or its
Assets, all of which are in full force and effect.

                                      -9-
<PAGE>

            3.11 Inventories. The Company has good and marketable title to the
Inventory, free and clear of all Encumbrances except for those Encumbrances
which will be released on or before the Closing Date. Except as otherwise
reserved against, as reflected in the financial information disclosed on
Schedule 3.05, all Inventory reflected in such financial information consists of
a quality and quantity usable and saleable in the ordinary course of business at
a commercial value at least equal to the value shown on such financial
information and is valued in accordance with GAAP net of reserves consistent
with the past practices of the Company at the lesser of current book value or
fair market value. All Inventory purchased since May 31, 2005 consists of a
quality and quantity usable and saleable in the ordinary course of business. All
Inventory is located on premises owned or leased by the Company. All
work-in-process of the Business is of a quality ordinarily produced in
accordance with the requirements of the order to which such work-in-process is
identified.

            3.12 Suppliers and Customers. Schedule 3.12 sets forth (a ) the ten
(10) largest suppliers of the Company during each of calendar years 2003 and
2004; and (b) the ten (10) largest customers of the Company during each of
calendar years 2003 and 2004. There exists no actual or threatened termination,
cancellation or limitation of, or any modification or change in, the Company's
business relationship with any customer or supplier, which termination,
cancellation, limitation, modification or change could, individually or in the
aggregate, be reasonably expected to have a Material Adverse Effect.

            3.13 Products. Schedule 3.13 lists each product under development,
developed, manufactured, licensed, distributed or sold by the Company and any
other products in which the Company has any proprietary rights or beneficial
interest (collectively, the "Products").

            3.14 Transactions With Affiliates. Except as set forth on Schedule
3.14, the Company has not purchased, acquired or leased any property or services
from, or sold, transferred or leased any property or services to, or loaned or
advanced any money to, or borrowed any money from, or entered into or been
subject to any management, consulting or similar agreement with, or engaged in
any other significant transaction with any officer, director or shareholder of
the Company or any of their respective Affiliates. Except as set forth on
Schedule 3.14, no shareholder or other Affiliate of the Company is indebted to
the Company for money borrowed or other loans or advances, and the Company is
not indebted to any shareholder or any such Affiliate.

            3.15 Operations Since May 31, 2005.

                  (a) Since May 31, 2005, there has not been any change,
      circumstance or effect in or with respect to the Assets, financial
      condition or results of operations of the Business, other than any
      changes, circumstances and effects arising in the ordinary course of
      business that have not had and would not be reasonably expected to have,
      individually or in the aggregate, a Material Adverse Effect.

                  (b) Since May 31, 2005, the Company has conducted the
      Business, in all material respects, in the ordinary course, and the
      Company has not:

                                      -10-
<PAGE>

                        (i) Conveyed, exchanged, sold, assigned, abandoned,
            leased (as lessor or lessee), transferred, licensed, or otherwise
            disposed of, in whole or in part, in a single transaction or series
            of related transactions, any Assets (including Intellectual
            Property) except in the ordinary course of business;

                        (ii) Suffered any damage, destruction or casualty loss
            with respect to the Assets (whether or not covered by insurance)
            material to the Business;

                        (iii) Incurred or guaranteed any indebtedness;

                        (iv) Made any material change in the accounting
            principles, methods, practices or policies relating to the Business,
            unless such change was required by GAAP;

                        (v) With respect to the Business, acquired or purchased
            any properties or assets that are, individually or in the aggregate,
            material to the Business (other than in the ordinary course of
            business), merged or consolidated with, or acquired all or
            substantially all of the assets of, or otherwise acquired, any
            Person, or made any material investment in any Person;

                        (vi) Executed, terminated, cancelled, materially
            modified or permitted to materially modify, terminate, cancel or
            expire any Business Contract;

                        (vii) Created or suffered the imposition of any
            Encumbrance on any of the Assets;

                        (viii) Forgiven or cancelled any material debt or
            material claim of the Business or voluntarily waived any right of
            material value, other than compromises of accounts receivable in the
            ordinary course of business;

                        (ix) Entered into any intercompany transactions relating
            to the Assets with any Affiliate of the Company; or

                        (x) Authorized, approved, agreed or committed to do any
            of the actions described in clauses (i)-(ix) above.

            3.16 Taxes. The Company has filed or will have filed on a timely
basis all material Tax Returns relating to the Business in connection with any
Tax required to be filed by it, and the Company has or will have timely paid all
such Taxes shown thereon to be due. None of the Assets is subject to any lien in
favor of the United States pursuant to Section 6321 of the Code for nonpayment
of federal Taxes, or any lien in favor of any state or locality pursuant to any
comparable provision of state or local law, under which transferee liability
might be imposed upon Buyer as a buyer of such Assets pursuant to Section 6323
of the Code or any comparable provision of state or local law. None of the
Assets is tax-exempt use property within the meaning of Section 168(h) of the
Code. There is no Action, audit or claim now pending with respect to any Tax
with respect to the Assets. There are no outstanding agreements extending the
statutory period of limitation applicable to any claim for, or the period for
the collection or

                                      -11-
<PAGE>

assessment of, Taxes with respect to the Assets. With respect to the Business,
the Company has duly and timely withheld from employee salaries, wages and other
compensation and paid over to the appropriate taxing authorities all amounts
required to be so withheld and paid over for all periods under all applicable
laws. With respect to the Business, the Company has collected all material sales
and use Taxes required to be collection and has remitted, or will remit on a
timely basis, such amounts to the appropriate taxing authority, or has been
furnished properly completed exemption certificates and has maintained all such
records and supporting documents in the manner required by all applicable sales
and use Tax statutes and regulations.

            3.17 Intentionally Omitted.

            3.18 Intellectual Property.

                  (a) Schedule 3.18 contains a list of all Marks owned or used
      by the Company as of the date of this Agreement which relate to the
      Business as presently conducted.

                  (b) Except as set forth on Schedule 3.18, the Company either:
      (i) owns the entire right, title and interest in and to all Intellectual
      Property that is used in the Business as presently conducted (the
      "Business Intellectual Property"), free and clear of Encumbrances or
      adverse claims of ownership from current or former employees and
      contractors; or (ii) has the right and license to use the Business
      Intellectual Property in the conduct of the Business.

                  (c) To the Knowledge of the Company, except as set forth on
      Schedule 3.18, all items set forth on Schedule 3.18 are valid and in
      force, or to the extent such items are applications, are pending without
      challenge.

                  (d) (i) During the previous three (3) years, no material
      Action has been taken or, to the Knowledge of the Company, threatened, (A)
      alleging that the conduct of the Business or any Business Intellectual
      Property infringes on or misappropriates the Intellectual Property of
      another Person; or (B) challenging the ownership or validity of the
      Business Intellectual Property; (ii) no material Action is pending with
      respect to any Business Intellectual Property; and (iii) to the Knowledge
      of the Company, there is no valid basis for any Action described in this
      Section 3.18.

            3.19 Environmental; Health; Safety. To the Knowledge of the Company,
the Company is in compliance in all material respects with all applicable
environmental laws. There is no environmental litigation, administrative or
judicial proceeding or order, consent decree, or investigation pending or
threatened against the Company related to the Business.

            3.20 No Undisclosed Liabilities.

                  (a) The Business does not have any Liabilities of any nature
      except for (i) Liabilities disclosed, reflected or reserved against in the
      Interim Balance Sheet, (ii) Liabilities incurred since May 31, 2005 in the
      ordinary course of business and which have not and will not result in a
      Material Adverse Effect, (iii) Liabilities incurred in

                                      -12-
<PAGE>

      connection with this Agreement and the transactions contemplated hereby
      and (iv) Liabilities which would not have a Material Adverse Effect on the
      Assets.

                  (b) Except as set forth on Schedule 3.20, the Business does
      not have any Indebtedness.

            3.21 Accounts Receivable. All accounts receivable of the Company
(collectively, the "Accounts Receivable") represent or shall represent valid
obligations arising from sales actually made or services actually performed in
the ordinary course of business. The Accounts Receivable are or will be as of
the Closing Date fully collectible, net of the reserves shown on the Interim
Balance Sheets or on the accounting records of the Company as of the Closing
Date (which reserves are adequate and calculated consistent with past practice).
To the Knowledge of the Company, there is no contest, claim, or right of set
off, other than returns in the ordinary course of business, under any Contract
with any obligor of an Accounts Receivable relating to the amount or validity of
such Accounts Receivable. Schedule 3.21 contains a complete and accurate list of
all Accounts Receivable as of May 31, 2005, which list sets forth the aging of
such Accounts Receivable.

            3.22 Investment Representations. Each of Symco and Symbiotics (each,
a "Holder") represents and warrants to Buyer that:

                  (a) Investment Representations. Holder understands that the
      Note has not been registered under the Securities Act of 1933, as amended
      (the "Securities Act"). Holder also understands that the Note is being
      offered and sold pursuant to an exemption from registration contained in
      the Securities Act based in part upon Holder's representations contained
      in the Agreement.

                  (b) Experience; Risk. Holder has such knowledge and experience
      in financial and business matters that Holder is capable of evaluating the
      merits and risks of the purchase of the Note and of protecting Holder's
      interests in connection therewith. Holder is able to fend for itself in
      the transactions contemplated by this Agreement and has the ability to
      bear the economic risk of the investment, including complete loss of the
      investment. The foregoing does not, however, limit or modify (i) the
      representations, warranties, agreements or covenants of the Buyer set
      forth in this Agreement (or those of Naturade set forth in, or assumed
      pursuant to, the Assignment and Assumption Agreement); (ii) the right of
      the Company to rely thereon or (iii) the obligation of Buyer to perform
      its obligations under this Agreement and the Note and other Collateral
      Agreements (including by way of illustration and not by way of limitation
      to comply with the payment requirements of the Note) (or the obligation of
      Naturade to perform such obligations and those in the Assignment and
      Assumption Agreement upon and following Naturade's execution of the
      Assignment and Assumption Agreement).

                  (c) Investment. Holder is acquiring the Note for investment
      for its own account, not as a nominee or agent, and not with a view to, or
      for resale in connection with, any distribution thereof, and Holder has no
      present intention of selling, granting any participation in, or otherwise
      distributing the same. Holder understands that the Note has not been
      registered under the Securities Act and applicable state securities

                                      -13-
<PAGE>

      laws (collectively, the "Acts") by reason of a specific exemption from the
      registration provisions of the Acts which depends upon, among other
      things, the bona fide nature of the investment intent and the accuracy of
      Holder's representations as expressed herein.

                  (d) Restricted Note. Holder understands that the Note will be
      a "restricted security" under applicable securities laws inasmuch as it is
      being acquired from the Company in a transaction not involving a public
      offering and that under such laws and applicable regulations the Note may
      be resold without registration under the Acts only in certain limited
      circumstances. Holder acknowledges that the Note must be held indefinitely
      unless subsequently registered under the Acts or an exemption from such
      registration is available.

                  (e) Accredited Investor. Holder is an "accredited investor"
      within the meaning of Rule 501 promulgated under the Securities Act. The
      Holder has considered the federal and state income tax implications of an
      investment in the Note and has consulted with his own advisors with
      respect thereto.

                  (f) Further Limitations on Disposition. Without in any way
      limiting the representations set forth above, Holder further agrees not to
      make any disposition of all or any portion of the Note unless and until:

                        (i) there is then in effect a registration statement
            under the Acts covering such proposed disposition and such
            disposition is made in accordance with such registration statement;
            or

                        (ii) Holder shall have notified the Company of the
            proposed disposition, and shall have furnished the Company with a
            statement of the circumstances surrounding the proposed disposition,
            and, at the expense of Holder or its transferee, with an opinion of
            counsel, reasonably satisfactory to the Company, that such
            disposition will not require registration of such securities under
            any of the Acts.

            3.23 Other Information. The information furnished by the Company to
Buyer pursuant to this Agreement (including, without limitation, information
contained in the exhibits hereto, the Schedules identified herein, the
instruments referred to in such Schedules and the certificates and other
documents to be executed or delivered pursuant hereto by the Company at or prior
to the Closing) is not, nor at the Closing will be, false or misleading in any
material respect, or contains, or at the Closing will contain, any misstatement
of material fact, or omits, or at the Closing will omit, to state any material
fact required to be stated in order to make the statements therein not
misleading.

                                   ARTICLE IV
                     REPRESENTATIONS AND WARRANTIES OF BUYER

            Buyer hereby represents and warrants to the Company that:

            4.01 Corporate Existence and Qualification. Buyer is a corporation
duly organized, validly existing and in good standing under the laws of the
Bahamas; has the

                                      -14-
<PAGE>

corporate power to own, manage, lease and hold its properties and to carry on
its business as and where such properties are presently located and such
business is presently conducted; and is duly qualified to do business and is in
good standing as a foreign corporation in each of the jurisdictions where the
character of its properties or the nature of its business requires it to be so
qualified.

            4.02 Authority, Approval and Enforceability. This Agreement has been
duly executed and delivered by Buyer and Buyer has all requisite corporate power
and legal capacity to execute and deliver this Agreement and all Collateral
Agreements executed and delivered or to be executed and delivered by Buyer in
connection with the transactions provided for hereby, to consummate the
transactions contemplated hereby and by the Collateral Agreements, and to
perform its obligations hereunder and under the Collateral Agreements. The
execution and delivery of this Agreement and the Collateral Agreements and the
performance of the transactions contemplated hereby and thereby have been duly
and validly authorized and approved by all corporate action necessary on behalf
of Buyer. This Agreement and each Collateral Agreement to which Buyer is a party
constitutes, or upon execution and delivery will constitute, the legal, valid
and binding obligation of Buyer, enforceable in accordance with its terms,
except as such enforcement may be limited by general equitable principles or by
applicable bankruptcy, insolvency, moratorium, or similar laws and judicial
decisions from time to time in effect which affect creditors' rights generally.

            4.03 No Proceedings. No suit, action or other proceeding is pending
or, to Buyer's knowledge, threatened, before any Governmental Authority seeking
to restrain Buyer or prohibit its entry into this Agreement or prohibit the
Closing.

            4.04 No Conflict. The execution and delivery by Buyer of this
Agreement and each Collateral Agreement, and the performance by it of its
obligations hereunder and thereunder, does not and will not:

                  (a) Violate any provision of the certificate of incorporation
      or bylaws of Buyer;

                  (b) Violate any provision of any Legal Requirement relating to
      Buyer, or require a registration, filing, application, notice, consent,
      approval, order, qualification, authorization, designation, declaration or
      waiver with, to or from any Governmental Authority; or

                  (c) Require a consent, approval or waiver from, or notice to,
      any party, or result in a breach of, constitute (with or without due
      notice or lapse of time or both) a default under, or create in any party
      the right to terminate, cancel or modify, any contract.

            4.05 Financing. Buyer has, or will have as of the Closing Date,
sufficient financial resources to fulfill all of its obligations due under this
Agreement and all Collateral Agreements as of the Closing Date.

                                      -15-
<PAGE>

                                   ARTICLE V
               CONDITIONS TO THE COMPANY'S AND BUYER'S OBLIGATIONS

            5.01 Conditions to Obligations of the Company. The obligations of
the Company to carry out the transactions contemplated by this Agreement are
subject, at the option of the Company, to the satisfaction or waiver of the
following conditions:

                  (a) All representations and warranties of Buyer contained in
      this Agreement shall be true and correct in all material respects at and
      as of the Closing, and Buyer shall have performed and satisfied in all
      material respects all covenants and agreements required by this Agreement
      to be performed and satisfied by Buyer at or prior to the Closing, and the
      Company shall have received a certificate to such effect from an officer
      of Buyer.

                  (b) As of the Closing Date, no Action shall be pending or
      threatened before any Governmental Authority seeking to restrain the
      Company or prohibit the Closing or seeking Damages against Buyer or the
      Company as a result of the consummation of this Agreement.

                  (c) All of Buyer's deliveries (described in Section 2.03)
      shall be tendered to the Company at or prior to Closing.

                  (d) The Buyer shall have furnished the Company with a
      certified copy of all necessary corporate action on its behalf approving
      the Buyer's execution, delivery and performance of this Agreement and any
      Collateral Agreement.

                  (e) All proceedings to be taken by Buyer in connection with
      the transactions contemplated hereby and all documents incident thereto
      shall be reasonably satisfactory in form and substance to the Company and
      its counsel, and the Company and said counsel shall have received all such
      counterpart originals or certified or other copies of such documents as it
      or they may reasonably request.

                  (f) No proceeding in which Buyer shall be a debtor, defendant
      or party seeking an order for its own relief or reorganization shall have
      been brought or be pending by or against Buyer under any United States or
      state bankruptcy or insolvency law.

            5.02 Conditions to Obligations of Buyer. The obligations of Buyer to
carry out the transactions contemplated by this Agreement are subject, at the
option of Buyer, to the satisfaction, or waiver by Buyer, of the following
conditions:

                  (a) All representations and warranties of the Company
      contained in this Agreement shall be true and correct in all material
      respects at and as of the Closing, the Company shall have performed and
      satisfied in all material respects all agreements and covenants required
      by this Agreement to be performed and satisfied by it at or prior to the
      Closing, and Buyer shall have received a certificate of such effect from
      an officer of the Company.

                                      -16-
<PAGE>

                  (b) As of the Closing Date, no Action shall be pending or
      threatened before any Governmental Authority seeking to restrain Buyer or
      prohibit the Closing or seeking Damages against Buyer or the Company or
      the Assets as a result of the consummation of this Agreement.

                  (c) The Company shall have furnished Buyer with a certified
      copy of all necessary corporate action on its behalf approving the
      Company's execution, delivery and performance of this Agreement and each
      Collateral Agreement.

                  (d) All proceedings to be taken by the Company in connection
      with the transactions contemplated hereby and all documents incident
      thereto shall be satisfactory in form and substance to Buyer and its
      counsel, and Buyer and said counsel shall have received all such
      counterpart originals or certified or other copies of such documents as it
      or they may reasonably request.

                  (e) No proceeding in which the Company shall be a debtor,
      defendant or party seeking an order for its own relief or reorganization
      shall have been brought or be pending by or against the Company under any
      United States or state bankruptcy or insolvency law.

                  (f) All of the Company's deliveries (described in Section
      2.02) shall be tendered to Buyer at or prior to the Closing.

            5.03 Disclosure Supplement. The Company shall have the right to
supplement its disclosure to Buyer with respect to any matter arising after the
date of this Agreement that, if existing or occurring on or prior to the date of
this Agreement, would have been required to be set forth or described in any
schedule hereto. If such additional information set forth in such supplement
(together with any additional information set forth in the disclosure schedules
and any prior supplement) reveal facts, events or circumstances that Buyer
reasonably believes will have, individually or in the aggregate, a Material
Adverse Effect, then the condition stated in Section 5.02(a) shall be deemed not
to have been satisfied and this Agreement may be terminated by Buyer.

            5.04 Name Change. On or before September 30, 2005, the Company shall
change its name at Closing and discontinue all use of the name "Symbiotics" and
"Symco."

                                   ARTICLE VI
                              ADDITIONAL AGREEMENTS

            6.01 Further Assurances. Following the Closing, the Company and the
Buyer shall execute and deliver such documents, and take such other action, as
shall be reasonably requested by any other party hereto to carry out the
transactions contemplated by this Agreement.

            6.02 Publicity. None of the parties hereto shall issue or make, or
cause to have issued or made, any public release or announcement concerning this
Agreement or the transactions contemplated hereby, without the advance approval
in writing of the form and substance thereof by each of the other parties,
except as required by law or by the rules of the

                                      -17-
<PAGE>

National Association of Securities Dealers or the United States Securities and
Exchange Commission (in which case, so far as possible, there shall be
consultation among the parties prior to such announcement), and the parties
shall endeavor jointly to agree on the text of any announcement or circular so
approved or required.

            6.03 Conduct of the Business Prior to the Closing Date. From the
date hereof until the Closing Date, the Company shall operate the Business only
in the ordinary course of business, and shall not engage in any of the actions
described in Section 3.15 without the written consent of Buyer.

            6.04 Confidential Information. The Company acknowledges that all
customer, supplier and distributor lists, manufacturing techniques, formulas,
sales, marketing and expansion strategies, technology, processes of the Company
and Buyer relating to the business conducted with the Assets, and all related
information concerning the products, services, production, development,
technology and all related technical information, procurement, and sales
activities and procedures, promotion, and pricing techniques, and credit
financial data relating to the business conducted with the Assets concerning
customers of the Company and Buyer are valuable, special, and unique assets
(collectively, "Confidential Information"). The parties agree that all
Confidential Information of the Company shall be transferred to Buyer as part of
the Assets pursuant to the terms of this Agreement. In recognition of this,
Company represents and agrees that during the three (3) year period following
the date of this Agreement, Company will not (i) disclose any Confidential
Information to any Person or entity, or (ii) make use of any Confidential
Information for its own purposes or for the benefit of any Person or entity
other than Buyer, except for disclosures required by any Legal Requirement, in
which event Buyer shall be given prompt notice of any such compelled disclosure,
and, if possible, opportunity to defend its rights hereunder prior to any such
compelled disclosure being made. The Company acknowledges that this covenant to
maintain Confidential Information is necessary to protect the goodwill and
proprietary interest of the Company and that restriction against disclosure of
Confidential Information is reasonable in light of the consideration and other
value the Company has accepted pursuant to this Agreement. Notwithstanding the
foregoing, nothing in this Section 6.04 shall apply to activities of the Company
or its Affiliates which are expressly permitted under Section 6.08.

            6.05 Transition. Immediately after the Closing Date, Buyer and the
Company shall agree in writing upon a process for handling orders and product
shipments during a reasonable transition period following the Closing Date.
Buyer and the Company shall also agree in writing upon a process for introducing
Buyer to the Company's customers and notifying the Company's customers of
Buyer's purchase of the Assets. Any and all of the Company's press releases to
the public regarding the transaction contemplated by this Agreement, and
communications to vendors and customers regarding the transaction reasonably
contemplated by this Agreement shall be approved by Buyer in writing.

            6.06 Intentionally Omitted.

            6.07 Exclusivity. From the date hereof until the earlier of the
Closing Date or the termination of this Agreement pursuant to Section 8.13, the
Company shall not, and shall use reasonable commercial efforts to cause its
officers, directors, employees, representatives and

                                      -18-
<PAGE>

agents not to, (a) initiate, solicit or encourage any proposal, offer or
discussion with any Person (other than Buyer) concerning any merger, business
combination, sale of stock or sale of assets (other than sales of assets in the
ordinary course of business) involving the Business or (b) engage in discussions
or negotiations with any Person (other than Buyer) concerning any such
transaction.

            6.08 Covenant Not to Compete.

                  (a) With respect to retail sales channels, for a period of
      three years from and after the Closing Date, the Company shall not,
      directly or indirectly through any of its Affiliates or otherwise, engage
      in the manufacture, sale, provision or distribution of any Products, or
      enter into any arrangement (contractual or otherwise) pursuant to which
      any other Person agrees on behalf of the Company or any of its Affiliates
      to do any of the foregoing. Buyer and the Company expressly agree that
      nothing in this Section 6.08 shall apply to the Company or its Affiliates
      with respect to business operations in network or multi-level marketing
      channels.

                                  ARTICLE VII
                                   INDEMNITY

            7.01 Indemnification.

                  (a) Each of Symco and Symbiotics shall jointly and severally
      indemnify, defend and hold harmless Buyer its Affiliates, and its
      partners, shareholders, directors, officers, employees, agents and
      representatives (collectively, the "Buyer Indemnified Parties") from and
      against any and all Liabilities, judgments, claims, settlements, losses,
      damages, costs, fees (including reasonable attorneys' fees, court fees and
      expenses), liens, taxes, penalties, obligations and expenses incurred or
      suffered (collectively, "Losses") by any such Buyer Indemnified Party
      arising from (collectively, the "Buyer Indemnifiable Claims"):

                        (i) any misrepresentation or breach of any
            representation, warranty or agreement of the Company contained in
            this Agreement;

                        (ii) the non-fulfillment by the Company of any covenant
            or agreement made by such party in this Agreement;

                        (iii) any obligation arising from the conduct of the
            Business on or prior to the Closing;

                        (iv) Liability that is not an Assumed Liability;

                        (v) without limiting the foregoing, all Liabilities for
            Taxes incurred by the Company related to or arising as a result of
            the conduct of the Company or the Business on or prior to the
            Closing Date;

                        (vi) the failure of the Company or Buyer to comply with
            any bulk sales law; and

                                      -19-
<PAGE>

                        (vii) any and all Losses incident to any of the matters
            referred to in clauses (i) through (vi) of this Section 7.01(a).

                  (b) Buyer shall indemnify, defend and hold harmless the
      Company, its Affiliates and its partners, shareholders, directors,
      officers, employees and other agents and representatives (collectively
      "Company Indemnified Parties"), from and against any and all Losses
      incurred or suffered by any Company Indemnified Party, arising from:

                        (i) any misrepresentation or breach of any
            representation, warranty or agreement of Buyer contained in this
            Agreement;

                        (ii) the non-fulfillment by Buyer of any covenant or
            agreement made by it in this Agreement;

                        (iii) any and all Assumed Liabilities;

                        (iv) any obligation arising from the conduct of the
            Business after the Closing by Buyer; and

                        (v) any and all Losses incident to any of the matters
            referred to in clauses (i) through (iv) of this Section 7.01(b).

            7.02 Notice of Asserted Liability. Promptly after a Buyer
Indemnified Party or Company Indemnified Party (in this context, an
"Indemnitee") become aware of any fact, condition or event that may give rise to
Losses for which indemnification may be sought under this Article VII, the
Indemnitee shall give notice thereof in the manner provided in Section 8.03 of
this Agreement (the "Claims Notice") to the party (in this context, the
"Indemnitor"). The Claims Notice shall include a description in reasonable
detail of any claim or the commencement (or threatened commencement) of any
action, proceeding or investigation (an "Asserted Liability") against
Indemnitee, and shall indicate the amount (estimated, if necessary) of the
Losses that have been or may be suffered by Indemnitee. Failure of Indemnitee to
promptly give notice hereunder shall not affect rights to indemnification
hereunder, except to the extent that Indemnitor demonstrates actual damage
caused by such failure. Upon Indemnitor's request, Indemnitee shall provide
Indemnitor with such reasonable documentation as Indemnitor shall request
pertaining to any claim(s) made by Indemnitee.

            7.03 Opportunity to Defend. Indemnitor may elect to compromise or
defend, at its own expense and by its own counsel reasonably acceptable to
Indemnitee, any Asserted Liability; provided, however, that Indemnitor may not
compromise or settle any Asserted Liability without the consent of Indemnitee,
such consent not to be unreasonably withheld, unless such compromise or
settlement requires no more than a monetary payment for which Indemnitee and any
other indemnifiable parties hereunder are fully indemnified or involves other
matters not binding upon Indemnitee or such other indemnifiable parties. If
Indemnitor elects to compromise or defends such Asserted Liability, it shall
within 15 business days (or sooner, if the nature of the Asserted Liability so
requires) notify Indemnitee of its intent to do so and Indemnitee shall
cooperate in the compromise of, or defense against, such Asserted Liability. If
Indemnitor elects not to compromise or defend any Asserted Liability, fails to
notify Indemnitee of its election as herein provided or contests its obligation
to indemnify, Indemnitee may pay,

                                      -20-
<PAGE>

compromise or defend such Asserted Liability, at the sole cost and expense of
Indemnitor, without prejudice to any rights Indemnitee may have hereunder. In
such event, Indemnitor may participate, at its own expense, in the defense of
any Asserted Liability in respect of which it may have an indemnification
obligation under Section 7.01, provided that Indemnitee shall control such
defense. If either party chooses to defend or participate in the defense of any
Asserted Liability, it shall have the right to receive from the other party any
books, records or other documents within such party's control that are necessary
or appropriate for such defense.

            7.04 Limitations. The indemnification and reimbursement obligations
hereunder, and the representations and warranties contained in this Agreement,
shall expire eighteen (18) months after the Closing Date (the "Expiration
Date"), except (a) as to any claims for, or any claims made or specifically
threatened by a third party that may result in, any liability, judgment, claim,
settlement, loss, damage, fee, lien, Tax, penalty, obligation or expense for
which indemnity has been (or may be in the case of third party specifically
threatened claims) sought hereunder of which the Indemnitor has received written
notice consistent with Section 7.02 from the Indemnitee on or before the
Expiration Date and (b) with respect to Taxes, the Expiration Date shall be 90
days after expiration of the latest statute of limitations applicable to such
Taxes. No Indemnitee shall be entitled to indemnification pursuant to this
Article VII if the Indemnitor shall have delivered in the aggregate funds equal
to Two Million Dollars ($2,000,000) in satisfaction of claims under this Article
VII.

            7.05 Right of Set-Off. Except as specifically permitted in this
Section 7.05, Buyer shall not have any right to withhold, reduce or set-off
against any amounts otherwise payable under the Note any amount owed, or claimed
to be owed, to Buyer by the Company. Buyer agrees to assert any claim, demand,
or other right against the Company not specifically permitted in this paragraph
only by an independent proceeding. Upon notice to the Company given not later
than ninety (90) days after the Closing Date specifying in reasonable detail the
basis for such set-off, Buyer may set off the amount to which it may be entitled
under this Section 7 against amounts otherwise payable under the Note provided
that the amount of such set-off claim is not less than $175,000 and provided
further that cash equal to the amount of the claimed set-off is delivered to an
independent third party reasonably acceptable to Buyer and the Company to be
held by such third party until the set-off claim is finally resolved in a
proceeding permitted under this Agreement. The exercise of such right of set-off
by Buyer in good faith, whether or not ultimately determined to be justified,
will not constitute an event of default under the Note. Neither the exercise of
nor the failure to exercise such right of set-off will constitute an election of
remedies or limit Buyer in any manner in the enforcement of any other remedies
that may be available to it.

                                  ARTICLE VIII
                                  MISCELLANEOUS

            8.01 Brokers. Regardless of whether the Closing shall occur, (i) the
Company shall indemnify and hold harmless Buyer from and against any and all
liability for any brokers or finders' fees arising with respect to brokers or
finders retained or engaged by the Company in respect of the transactions
contemplated by this Agreement, and (ii) Buyer shall indemnify and hold harmless
the Company from and against any and all liability for any brokers' or finders'
fees

                                      -21-
<PAGE>

arising with respect to brokers or finders retained or engaged by Buyer in
respect of the transactions contemplated by this Agreement.

            8.02 Costs and Expenses. Each of the parties to this Agreement shall
bear his or its own expenses incurred in connection with the negotiation,
preparation, execution and closing of this Agreement and the transactions
contemplated hereby.

            8.03 Notices. Any notice, request, instruction, correspondence or
other document to be given hereunder by any party hereto to another (herein
collectively called "Notice") shall be in writing and delivered personally or
mailed by registered or certified mail, postage prepaid and return receipt
requested, or sent by national commercial courier service, return receipt
requested for next day delivery to be confirmed in writing by such courier, or
by telecopier, as follows:

      BUYER:                         Quincy Investments Corp.
                                     309 Terraces North
                                     47-111 Vintage Drive East
                                     Indian Wells, California 92210
                                     Attention:  Peter H. Pocklington

                                     Telecopier No.:  760-862-2752

                                     With a Copy (which shall not constitute
                                     notice) to:

                                     Varner, Saleson & Brandt LLP
                                     3750 University Avenue, Suite 610
                                     Riverside, California 92501
                                     Attention:  Vahe Sarrafian

                                     Telecopier No.: 951-274-7770

      COMPANY:                       Symco, Inc. and/or Symbiotics, Inc.
                                     2301 West Highway 89A, Suite 107
                                     Sedona, Arizona  86336
                                     Attention:  Douglas Wyatt

                                     Telecopier No.:  928-203-0279

                                     With a Copy (which shall not constitute
                                     notice) to:

                                     16277 Windpiper Road
                                     Poway, California  92064
                                     Attention:  David Brown

                                     Telecopier No.:  658-535-0405

                                      -22-
<PAGE>

Each of the above addresses for notice purposes may be changed by providing
appropriate notice hereunder. Notice given by personal delivery or registered
mail shall be effective upon actual receipt. Notice given by telecopier shall be
effective upon actual receipt if received during the recipient's normal business
hours, or at the beginning of the recipient's next normal business day after
receipt if not received during the recipient's normal business hours. All
Notices by telecopier shall be confirmed by the sender thereof promptly after
transmission in writing by registered mail or personal delivery.

            8.04 Governing Law, Jurisdiction, Venue, Waiver and Jury Trial. The
provisions of this agreement and the documents delivered pursuant hereto shall
be governed by and construed in accordance with the laws of the State of
California (excluding any conflict of law rule or principle that would refer to
the laws of another jurisdiction). Each party hereto irrevocably submits to the
jurisdiction of the State of California, Los Angeles or Orange County, in any
action or proceeding arising out of or relating to this Agreement or any of the
Collateral Agreements, and each party hereby irrevocably agrees that all claims
in respect of any such action or proceeding must be brought and/or defended in
such court; provided, however, that matters which are under the exclusive
jurisdiction of the Federal courts shall be brought in the Federal District
Court for the Central District of California. Each party hereto consents to
service of process by any means authorized by the applicable law of the forum in
any action brought under or arising out of this Agreement or any of the
Collateral Agreements, and each party irrevocably waives, to the fullest extent
each may effectively do so, the defense of an inconvenient forum to the
maintenance of such action or proceeding in any such court. EACH PARTY HERETO
HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY
LEGALLY AND EFFECTIVELY DO SO, TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING
ARISING HEREUNDER.

            8.05 Entire Agreement; Amendments and Waivers. This Agreement,
together with all exhibits and schedules attached hereto, constitutes the entire
agreement between and among the parties hereto pertaining to the subject matter
hereof and supersedes all prior agreements, understandings, negotiations and
discussions, whether oral or written, of the parties, and there are no
warranties, representations or other agreements between the parties in
connection with the subject matter hereof except as set forth specifically
herein or contemplated hereby. No supplement, modification or waiver of this
Agreement shall be binding unless executed in writing by the party to be bound
thereby. No waiver of any of the provisions of this Agreement shall be deemed or
shall constitute a waiver of any other provision hereof (regardless of whether
similar), nor shall any such waiver constitute a continuing waiver unless
otherwise expressly provided.

            8.06 Binding Effect and Assignment. This Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective
permitted successors and assigns; but neither this Agreement nor any of the
rights, benefits or obligations hereunder shall be assigned, by operation of law
or otherwise, by either party without the prior written consent of the other
party. The Company understands and consents to Buyer's assignment of all of its
rights and obligations under this Agreement to Naturade pursuant to the
Assignment and Assumption Agreement in the form attached as Exhibit F-2, and,
acknowledges that Naturade is an express third party beneficiary under this
Agreement. Except as set forth in the immediately prior sentence, nothing in
this Agreement, express or implied, is intended to confer upon any person or

                                      -23-
<PAGE>

entity other than the parties hereto and their respective permitted successors
and assigns, any rights, benefits or obligations hereunder.

            8.07 Remedies. The rights and remedies provided by this Agreement
are cumulative, and the use of any one right or remedy by any party hereto shall
not preclude or constitute a waiver of its right to use any or all other
remedies. Such rights and remedies are given in addition to any other rights and
remedies a party may have by law, statute or otherwise.

            8.08 Exhibits and Schedules. The exhibits and Schedules referred to
herein are attached hereto and incorporated herein by this reference. Disclosure
of a specific item in any one Schedule shall be deemed restricted only to the
Sections to which it is reasonably apparent on its face that it specifically
relates.

            8.09 Multiple Counterparts. This Agreement may be executed in one or
more counterparts and via facsimile, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument.

            8.10 References and Construction.

                  (a) Whenever required by the context, and is used in this
      Agreement, the singular number shall include the plural and pronouns and
      any variations thereof shall be deemed to refer to the masculine,
      feminine, neuter, singular or plural, as the identification the person may
      require. References to monetary amounts, specific named statutes and
      generally accepted accounting principles are intended to be and shall be
      construed as references to United States dollars, statutes of the United
      States of the stated name and United States generally accepted accounting
      principles, respectively, unless the context otherwise requires.

                  (b) The provisions of this Agreement shall be construed
      according to their fair meaning and neither for nor against any party
      hereto irrespective of which party caused such provisions to be drafted.
      Each of the parties acknowledge that it has been represented by an
      attorney in connection with the preparation and execution of this
      Agreement.

            8.11 Survival. Any provision of this Agreement which contemplates
performance or the existence of obligations after the Closing Date, and any and
all representations and warranties set forth in this Agreement, shall not be
deemed to be merged into or waived by the execution and delivery of the
instruments executed at the Closing, but shall expressly survive Closing and
shall be binding upon the party or parties obligated thereby in accordance with
the terms of this Agreement, subject to any limitations expressly set forth in
this Agreement.

            8.12 Attorneys' Fees. In the event any suit or other legal
proceeding is brought for the enforcement of any of the provisions of this
Agreement, the parties hereto agree that the prevailing party or parties shall
be entitled to recover from the other party or parties upon final judgment on
the merits reasonable attorneys' fees (and sales taxes thereon, if any),
including attorneys' fees for any appeal, and costs incurred in bringing such
suit or proceeding.

                                      -24-
<PAGE>

            8.13 Termination.

                  (a) This Agreement shall terminate on the earlier to occur of
      any of the following events:

                        (i) the mutual written agreement of Buyer and the
            Company;

                        (ii) by written notice of Buyer or the Company to the
            other party hereto, if the Closing shall not have occurred prior to
            12:00 midnight, Pacific Daylight time, on the 30th day after the
            date of this Agreement;

                        (iii) by written notice of Buyer to the Company, if the
            Company shall have materially breached any of their representations,
            warranties or agreements contained herein or pursuant to Section
            5.03; or

                        (iv) by written notice of the Company to Buyer, if Buyer
            shall have materially breached any of its representations,
            warranties or agreements contained herein.

                  (b) Nothing in this Section shall relieve any party of any
      liability for a breach of this Agreement prior to the termination hereof.
      Upon the termination of this Agreement, all other rights and obligations
      of the parties under this Agreement shall terminate, except their
      obligations under Sections 6.02, 6.04, 7.05, 8.02-8.05, 8.07 and
      8.10-8.12.

            8.14 Bulk Sales Laws. The parties hereby waive compliance with the
bulk sales laws of any state in which the Assets are located or in which
operations relating to the Business are conducted.

                                   ARTICLE IX
                                   DEFINITIONS

            Capitalized terms used in this Agreement are used as defined in this
Article IX or elsewhere in this Agreement.

            9.01 Action. The term "Action" shall mean any lawsuit, claim,
proceeding, litigation, arbitration, action, investigation, inquiry, cause of
action, right of recovery or chose in action.

            9.02 Affiliate. The term "Affiliate" shall mean, with respect to any
Person, any other Person controlling, controlled by or under common control with
such Person. The term "Control" as used in the preceding sentence means, with
respect to a corporation, the right to exercise, directly or indirectly, more
than 50% of the voting rights attributable to the shares of the controlled
corporation and, with respect to any Person other than a corporation, the
possession, directly or indirectly, of the power to direct or cause the
direction of the management or policies of such Person.

            9.03 Assets. Shall have the meaning set forth in Section 1.01.

                                      -25-
<PAGE>

            9.04 Business Day. The term "Business Day" shall mean any day that
national banks are open to conduct business in Irvine, California.

            9.05 Closing Date. Shall have the meaning set forth in Section 2.01.

            9.06 Code. The term "Code" shall mean the Internal Revenue Code of
1986, as amended.

            9.07 Collateral Agreements. The term "Collateral Agreements" shall
mean any or all of the exhibits to this Agreement and any and all other
agreements, instruments or documents required or expressly provided under this
Agreement to be executed and delivered in connection with the transactions
contemplated by this Agreement.

            9.08 Contract. The term "Contract" shall mean any written contract,
agreement, license, lease, guaranty, indenture, sales or purchase order or other
legally binding commitment in the nature of a contract to which the Company is a
party.

            9.09 Court Order. The term "Court Order" means any judgment, order,
writ, decision, injunction, award or decree of any foreign, federal, state,
local or other court or tribunal and any ruling or award in any arbitration
proceeding.

            9.10 Encumbrances. The term "Encumbrances" shall mean any lien,
encumbrance, claim, charge, security interest, mortgage, deed of trust, pledge,
easement, conditional sale or other title retention agreement, defect in title
or other restriction of a similar kind.

            9.11 Financial Statements. The term "Financial Statements" shall
have the meaning set forth in Section 3.05.

            9.12 GAAP. The term "GAAP" shall mean generally accepted accounting
principles, consistently applied.

            9.13 Governmental Authorities. The term "Governmental Authorities"
shall mean any nation or country (including but not limited to the United States
and the Bahamas) and any commonwealth, territory or possession thereof and any
political subdivision of any of the foregoing, including but not limited to
courts, departments, commissions, boards, bureaus, agencies, ministries or other
instrumentalities.

            9.14 Intellectual Property. The term "Intellectual Property" shall
mean any and all of the following which is owned by, licensed by, licensed to,
used or held for use by the Company (including all copies and embodiments
thereof, in electronic, written or other media): (a) all registered and
unregistered U.S. and foreign trade names, trademarks, trade dress and service
marks, together with any applications related thereto and the goodwill of the
Business symbolized thereby ("Marks"); (b) all inventions (whether patentable or
unpatentable), all improvements thereto, and all patent, patent applications and
disclosures related thereto, together with all reissuances, continuations,
continuations in part, revisions, extensions and re-examinations thereof and all
issued U.S. and foreign patents and pending patent applications, patent
disclosures and improvements thereto (collectively, the "Patents"); (c) all
registered and

                                      -26-
<PAGE>

unregistered U.S. and foreign works of authorship, fixed in any tangible medium
of expressions regardless of the availability of copyright protection, but
including all copyrights and moral rights recognized by law and all applications
to register and renewals of any of the foregoing ("Copyrights"); (d) all
categories of ideas, trade secrets, know-how, inventions (whether or not
patentable and whether or not reduced to practice), improvements, processes,
procedures, drawings, specifications, designs, plans, proposals, technical data,
copyrightable works, financial, marketing, and business data, pricing and cost
information, business and marketing plans, customer and supplier lists and
information, other confidential and proprietary information, manufacturing and
production processes and techniques, molds, dies, casts and product
configurations ("Proprietary Rights"); (e) all licenses and other Contracts
pursuant to which the Person has acquired rights in or to any of the Marks,
Patents, Copyrights, or Proprietary Rights ("In-Licenses"); and (f) all licenses
and other Contracts to which the Person has sold, licensed, leased or otherwise
transferred or granted any interest or rights to any Marks, Patents, Copyrights,
or Proprietary Rights ("Out-Licenses").

            9.15 Inventory. The term "Inventory" shall mean all goods,
merchandise and other personal property owned and held for sale, and all raw
materials, works-in-process, materials and supplies of every nature which
contribute to the finished products of the Company in the ordinary course of its
business, specifically excluding, however, damaged, defective or otherwise
unsaleable items.

            9.16 Knowledge. The term "Knowledge" with respect to any particular
matter, shall mean the actual knowledge of Douglas Wyatt, after reasonable due
inquiry of the employees of the Company who could be reasonably expected to be
knowledgeable about the facts relating to such matter.

            9.17 Legal Requirements. The term "Legal Requirements," when
described as being applicable to any Person, shall mean any and all laws
(statutory, judicial or otherwise), ordinances, regulations, judgments, orders,
directives, injunctions, writs, decrees or awards of, and any Contracts with,
any Governmental Authority, in each case as and to the extent applicable to such
Person or such Person's business, operations or properties.

            9.18 Liabilities. The term "Liabilities" shall mean all
indebtedness, obligations, damages, fines, fees, penalties, and other
liabilities (or contingencies that have not yet become liabilities), whether
absolute, accrued, matured, contingent (or based upon any contingency), known or
unknown, fixed or otherwise, or whether due or to become due, including without
limitation, any fines, penalties, judgments, awards or settlements respecting
any judicial, administrative or arbitration proceedings or any damages, losses,
claims or demands with respect to any Legal Requirement.

            9.19 Naturade. The term "Naturade" shall mean Naturade, Inc., a
Delaware corporation.

            9.20 Permits. The term "Permits" shall mean any and all permits,
rights, approvals, licenses, authorizations, legal status, orders or Contracts
under any Legal Requirement or otherwise granted by any Governmental Authority.

                                      -27-
<PAGE>

            9.21 Person. The term "Person" shall mean any individual,
partnership, joint venture, firm, corporation, association, limited liability
company, trust or other enterprise or any governmental or political subdivision
or any agency, department or instrumentality thereof.

            9.22 Taxes. The term "Taxes" shall mean any federal, state, local or
foreign income, gross receipts, estimated, profits, windfall profits, intangible
property, occupation, production, emergency excess, capital gains, capital
stock, stamp, goods and services, value-added property, sales, use, license,
excise, franchise, employment, payroll, withholding, alternative or add-on
minimum, ad valorem, transfer or excise tax, or any other tax, custom, duty,
governmental fee or other like assessment or charge of any kind whatsoever,
together with any interest or penalty, imposed by any Governmental Authority.

            9.23 Tax Returns. The term "Tax Returns" shall mean any return,
report or similar statement required to be filed with respect to any Tax
(including any attached schedules), including, without limitation, any
information return, claim for refund, amended return or declaration of estimated
Tax and any affiliated, consolidated, combined, unitary or similar return.

                         [SIGNATURES ON FOLLOWING PAGE]

                                      -28-
<PAGE>

                  [SIGNATURE PAGE TO ASSET PURCHASE AGREEMENT]

EXECUTED as of the date first written above.

                                        BUYER:

                                        Quincy Investments, Corp.,
                                        a Bahamas International Business Company

                                        By: /s/Peter H. Pocklington
                                            ------------------------------------
                                        Name: Peter H. Pocklington
                                        Title: Chairman

                                        COMPANY:

                                        Symco, Incorporated,
                                        a Nevada corporation

                                        By: /s/Douglas A. Wyatt
                                            ------------------------------------
                                        Name: Douglas A. Wyatt
                                        Title: CEO

                                        Symbiotics, Inc.,
                                        an Arizona corporation

                                        By: /s/Douglas A. Wyatt
                                            ------------------------------------
                                        Name: Douglas A. Wyatt
                                        Title: CEO

                                      S-1

               [Schedules and Exhibits have been omitted but are
             available to the staff of the Commission upon request]<PAGE>

                                                                    EXHIBIT 10.7

                       ASSIGNMENT AND ASSUMPTION AGREEMENT

            THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (the "Agreement") is made
and entered into as of this twenty-second day of July, 2005, by and among Symco,
Inc. and Symbiotics, Inc. (collectively, "Symbiotics"), Quincy Investments Corp.
("Quincy") and Naturade, Inc. (the "Company").

                               RECITALS

      A. The Company desires Quincy to identify, negotiate and arrange the
financing for the acquisition by the Company of selected assets of The Ageless
Foundation, Inc. and Symbiotics, in consideration for which Quincy shall be
entitled to receive Common Stock, Series C Convertible Preferred Stock and
warrants to purchase additional shares of Common Stock of the Company.

      B. Pursuant to that certain Master Investment Agreement dated July 22,
2005, (i) Quincy agreed to use its best efforts to enter into and perform its
obligations under that certain Asset Purchase Agreement, by and between Quincy
and Symbiotics, attached hereto as Exhibit A (the "Symbiotics Purchase
Agreement") and (ii) concurrent with the execution and delivery of the
Symbiotics Purchase Agreement, Quincy, the Company and Symbiotics agreed to
enter into this Agreement. This Agreement is the Assignment and Assumption
Agreement referred to in Sections 2.03(i). and 8.06 of the Symbiotics Purchase
Agreement.

      NOW, THEREFORE, in consideration of the foregoing and of the mutual
obligations herein contained, it is agreed as follows:

            1. ASSIGNMENT AND ACCEPTANCE.

                  (a) Quincy hereby assigns to the Company all of Quincy's
right, title and interest in, to and under the Symbiotics Purchase Agreement and
the Collateral Agreements (as defined in the Symbiotics Purchase Agreement) to
which Quincy is a party.

                  (b) The Company hereby accepts the foregoing assignment and
agrees to keep, perform and fulfill all of the terms, covenants, conditions,
duties and obligations which are required to be kept, performed and fulfilled by
Quincy under the Symbiotics Purchase Agreement and the Collateral Agreements to
which Quincy is a party and which terms, covenants, conditions, duties and
obligations are to be performed after the date hereof.

            2. ISSUANCE OF SECURITIES.

                  (a) Concurrent with the execution and delivery of this
Agreement, the Company has (i) issued to Quincy, and caused its transfer agent
to deliver certificates to Quincy for, 21,232,715 shares of Common Stock and
(ii) issued and delivered to Quincy warrants to purchase up to 7,000,000 shares
of Common Stock, in substantially the form attached hereto as Exhibit B (the
"Warrants"), receipt of which shares and Warrants hereby is acknowledged by
Quincy.

                                      -1-
<PAGE>

                  (b) Quincy hereby represents and warrants to the Company that
all representations and warranties of Quincy contained in Section 4 of the
Master Investment Agreement referred to in Recital B are true and complete as
though made on and as of the date hereof.

            3. RELEASE.

                  (a) Except with respect to the Promissory Note dated of even
date herewith referred to in Section 1.04(a) of the Symbiotics Purchase
Agreement, with respect to the Guaranty of Peter H. Pocklington dated of even
date herewith or with respect to claims which may arise pursuant to the
intentional misconduct or fraud of Quincy, Symbiotics hereby fully, forever and
unconditionally releases, exonerates, waives, relinquishes, discharges, acquits,
relieves and covenants not to sue Quincy, or any of its officers, directors,
employees or agents, from any and all rights, claims, demands, debts,
obligations, liabilities, promises and agreements arising from or in connection
with the Symbiotics Purchase Agreement.

                  (b) Each party hereto understands and agrees that this Section
3 extends to all claims of whatever nature and kind, known and unknown,
suspected or unsuspected, and they each expressly waive any and all rights under
Section 1542 of the Civil Code of the State of California, which provides as
follows:

            A general release does not extend to claims which the creditor does
            not know or suspect to exist in his favor at the time of executing
            the release, which if known by him must have materially affected his
            settlement with the debtor.

Each party hereto expressly waives and releases any right or benefit which it
has or may have under Section 1542 of the Civil Code of the State of California,
as well as under the provisions of all comparable or similar statutes,
provisions of common law or other decisional law of any and all states of the
United States, to the full extent that it waives all such rights and benefits
pertaining to the matters released herein. In connection with such waiver and
relinquishment, each party hereto acknowledges that it may hereafter discover
claims presently unknown or unsuspected, or facts in addition to or different
from those which it now knows or believes to be true, with respect to the
matters released herein. Nevertheless, it is the intention of each party hereto
through this Agreement, fully, finally and forever to settle and release all
such matters, and all claims relative thereto, which do now exist, may exist or
heretofore have existed among them in connection with the matters set forth in
Section 3(a). In furtherance of such intention, the release herein given shall
be and remain in effect as a full and complete release of such matters
notwithstanding the discovery or existence of any such additional different
claims or facts relative thereto, and each party hereto hereby expressly assumes
the risk of any injury, loss or damage which may arise from this waiver.

            4. REPRESENTATIONS, WARRANTIES AND COVENANTS OF NATURADE TO
SYMBIOTICS. Naturade hereby represents and warrants to, and covenants with,
Symbiotics that:

                                      -2-
<PAGE>

                  (a) Corporate Existence and Qualification. Naturade is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware; has the corporate power to own, manage, lease and hold
its properties and to carry on its business as and where such properties are
presently located and such business is presently conducted; and is duly
qualified to do business and is in good standing as a foreign corporation in
each of the jurisdictions where the character of its properties or the nature of
its business requires it to be so qualified.

                  (b) Authority, Approval and Enforceability. This Agreement has
been duly executed and delivered by Naturade, and Naturade has all requisite
power and legal capacity to execute and deliver this Agreement and all
Collateral Agreements executed and delivered or to be executed and delivered by
Naturade in connection with the transactions provided for hereby, to consummate
the transactions contemplated hereby and by the Symbiotics Purchase Agreement
and the Collateral Agreements, and to perform its obligations hereunder and
under the Symbiotics Purchase Agreement and the Collateral Agreements. The
execution and delivery of this Agreement and the Collateral Agreements and the
performance of the transactions contemplated hereby and thereby (including by
way of illustration and not by way of limitation the transactions contemplated
by the Symbiotics Purchase Agreement) have been duly and validly authorized and
approved by all corporate action necessary on behalf of Naturade. This
Agreement, the Symbiotics Purchase Agreement and each Collateral Agreement to
which Naturade is a party (whether as a result of the original execution of such
agreement or by virtue of this Agreement) constitutes, or upon execution and
delivery will constitute, the legal, valid and binding obligation of Naturade,
enforceable in accordance with its terms, except as such enforcement may be
limited by general equitable principles or by applicable bankruptcy, insolvency,
moratorium, or similar laws and judicial decisions from time to time in effect
which affect creditors' rights generally.

                  (c) No Proceedings. No suit, action or other proceeding is
pending or, to Naturade's knowledge, threatened before any Governmental
Authority seeking to restrain Naturade or prohibit its entry into this Agreement
or prohibit the transactions contemplated hereby.

                  (d) Conflicts. The execution and delivery by the Naturade of
this Agreement and each Collateral Agreement to which it is a party (whether as
a result of the original execution of such agreement or by virtue of this
Agreement), and the performance by it of its obligations under this Agreement,
the Symbiotics Purchase Agreement and each such Collateral Agreement, does not
and will not:

                        i. Violate any provision of the certificate of
incorporation or bylaws of Naturade;

                        ii. Violate any provision of any Legal Requirement
relating to Naturade, or require a registration, filing, application, notice,
consent, approval, order, qualification, authorization, designation, declaration
or waiver with, to or from any Governmental Authority (except such as may have
been made or obtained); or

                                      -3-
<PAGE>

                        iii. Require a consent, approval or waiver from, or
notice to, any party, or result in a breach of, constitute (with or without due
notice or lapse of time or both) a default under, or create in any party the
right to terminate, cancel or modify, any Contract (except such as may have been
made or obtained).

                  (e) Financing. Naturade has, or will have as of the due date
therefore, sufficient financial resources to fulfill all of its obligations
under this Agreement, the Symbiotics Purchase Agreement and each Collateral
Agreement. Naturade will diligently pursue any additional financing that may be
necessary to perform its obligations to be performed after the Closing Date.

                  (f) Reports. Naturade has filed all required forms, reports
and documents with the Securities and Exchange Commission (the "SEC"), all of
which, when filed, complied in all material respects with all applicable
requirements of the Securities Act of 1933, as amended, and the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder (the "SEC Reports"). None of the SEC Reports, when made, contained
any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary to make the statements therein not
misleading. Each of the balance sheets (including the related notes) included in
the SEC Reports fairly presents the consolidated financial position of Naturade
as of the respective dates thereof, and the other related statements (including
the related notes) included therein fairly present the consolidated results of
operations and the changes in consolidated financial position of Naturade for
the respective periods indicated therein, except, in the case of interim
financial statements, for year-end audit adjustments, consisting only of normal
recurring accruals which individually and in the aggregate are not material.
Except as set forth in the SEC Reports, each of the financial statements
(including the related notes) included in the SEC Reports has been prepared in
accordance with generally accepted accounting principles consistently applied
during the periods involved, except as otherwise noted therein. Naturade has
maintained its books of account in the usual, regular and ordinary manner in
accordance with generally accepted accounting principles applied on a consistent
basis. Since March 31, 2005, no material adverse change has occurred in the
assets or liabilities, condition, financial or otherwise, or business or in the
results of operations or prospects of Naturade, other than as reflected in the
SEC Reports.

                  (g) Compliance with Legal Requirements. Naturade is and has
been in compliance in all material respects with any and all Legal Requirements
applicable to Naturade.

                  (h) Environmental; Health; Safety. Naturade and its Affiliates
is in compliance in all material respects with all applicable environmental
laws. There is no environmental litigation, administrative or judicial
proceeding or order, consent decree, or investigation pending or threatened
against Naturade or its Affiliates.

                  (i) Title to Assets. Naturade owns, and has good and valid
title to all assets identified in its financial statements. Except as set forth
in its financial statements (or related notes thereto, all of said assets are
owned by Naturade free and clear of any Encumbrances. Naturade has no material
assets except as described in its financial statements.

                                      -4-
<PAGE>

            5. ENTIRE AGREEMENT. This Agreement embodies the entire agreement
and understanding between the parties hereto with respect to the subject matter
hereof and supersedes all prior and contemporaneous agreements and
understandings relating to such subject matter.

            6. AMENDMENT. This Agreement may not be amended except by written
document executed by the parties hereto.

            7. SUBJECT HEADINGS. Subject headings are included for convenience
only and shall not be deemed part of this Agreement.

            8. SEVERABILITY. If any provision of this Agreement shall be held
unenforceable as applied to any circumstance, the remainder of this Agreement
and the application of such provision to other circumstances shall be
interpreted so as best to effect the intent of the parties. The parties further
agree to replace any such unenforceable provision with an enforceable provision
(and to take such other action) which will achieve, to the extent possible, the
purposes of the unenforceable provision.

            9. GOVERNING LAW; JURISDICTION; VENUE. This Agreement shall be
governed by and construed under the laws of the State of California in force
from time to time. The parties hereto each, to the fullest extent it may
effectively do so under applicable law, irrevocably (i) submits to the exclusive
jurisdiction of any court of the State of California or the United States of
America sitting in the City of Los Angeles over any suit, action or proceeding
arising out of or relating to this Agreement, (ii) waives and agrees not to
assert, by way of motion, as a defense or otherwise, any claim that it is not
subject to the jurisdiction of any such court, any objection that it may now or
hereafter have to the establishment of the venue of any such suit, action or
proceeding brought in any such court and any claim that any such suit, action or
proceeding brought in any such court has been brought in an inconvenient forum,
and (iii) agrees that a final judgment in any such suit, action or proceeding
brought in any such court shall be conclusive and binding upon such party and
may be enforced in the courts of the United States of America or the State of
California (or any other courts to the jurisdiction of which such party is or
may be subject) by a suit upon such judgment.

            10. PARTIES BOUND. This Agreement is binding on and shall inure to
the benefit of the parties and their respective successors, assign, heirs, and
legal representatives.

            11. SURVIVAL. The representations, warranties, covenants, and
agreements contained in this Agreement shall survive the consummation of the
transactions contemplated hereby.

            12. COUNTERPARTS. This Agreement may be executed in one (1) or more
counterparts, each of which shall be deemed an original but all of which
together shall constitute one and the same instrument.

            13. DEFINITIONS. Except as otherwise defined in this Agreement,
capitalized terms used herein have the meanings set forth in the Symbiotics
Purchase Agreement.

                      The next page is the signature page.

                                      -5-
<PAGE>

            IN WITNESS WHEREOF, the parties have executed this Agreement as of
the date first above written.

                                      NATURADE, INC.

                                      By: /s/Stephen m. Kasprisin
                                          --------------------------------------
                                      Name: Stephen M. Kasprisin
                                      Title: Chief Financial Officer

                                      SYMCO, INC.

                                      By: /s/Douglas A. Wyatt
                                          --------------------------------------
                                      Name:  Douglas A. Wyatt
                                      Title: CEO

                                      SYMBIOTICS, INC.

                                      By: /s/Douglas A. Wyatt
                                          --------------------------------------
                                      Name:  Douglas A. Wyatt
                                      Title: CEO

                                      QUINCY INVESTMENTS CORP.

                                      By: /s/Peter H. Pocklington
                                          --------------------------------------
                                      Name: Peter H. Pocklington
                                      Title: Chairman

                                      -6-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}]]